Keeping track of the world's biggest killers

Magnus Grimond reports on an exiled professor who is pushing out the frontiers of medical science

If proof were needed that adversity is the crucible for creative genius, Salvador Moncada, the former head of research at drugs giant Wellcome, is surely it. Born of central European and Latin American parents, he knows better than most of us the pain of being forced out of your homeland.

His outlook has been forged by the experience of a family in permanent exile. His Jewish grandfather's forced emigration from Austria following Hitler's Anschluss in 1938 was followed 10 years later by his father having to flee his native Honduras after having fallen foul of the dictatorship which had come to power. By 1971, when Professor Moncada decided to quit Central America in disgust over the regime then terrorising his adopted El Salvador, he was following in a long family tradition.

But alongside this zeal to better the lot of his fellow man has burnt an equally strong desire to push out the frontiers of medical science. It is the triumph of that latter ambition which in the 1980s led Professor Moncada, while working at Wellcome, to the discovery of prostacyclin, a substance which stops blood clotting, and later to reveal the crucial importance of nitric oxide to the body's functioning. Former colleagues say that work brought him to within an ace of winning a Nobel prize. That same drive is now spurring him to establish the Cruciform Project, a ground- breaking attempt to set up a multi-disciplinary medical research facility bridging the gap between academia and industry.

For the past nine months, Professor Moncada and a team of 60 research scientists have set themselves up to unlock the secrets of some of the Western world's biggest killers. The research will concentrate on arteriosclerosis - heart attacks, strokes and the like; neuronal damage and repair - dealing with the after-effects of conditions such as stroke and Alzheimer's disease; and cancer.

But while millions of pounds are being thrown at similar research across the globe, the novelty of Professor Moncada's approach is the all-embracing nature of this new attack. Instead of being divided up into small teams, narrowly focused on specific disease areas, the Cruciform project will involve a large team of many disciplines working together using basic molecular science to achieve a common aim. The new institute, yet to be given a name, has attracted senior figures from both clinical science, such as Professor John Martin of the British Heart Foundation, and industry, including Professor Moncada's deputy, Ken Powell, formerly of Wellcome. Some 25 people from Wellcome's now-defunct research base at Beckenham in Kent have moved over to join Professor Moncada.

The significance of all this will not be lost on Britain's latest Nobel laureate, Sir Harold Croto, who warned this month that the low level of state funding meant research into basic science was "now below its survival threshold". The Government, he claimed, was using coercion to force scientists like him to work with industry.

The contrast with Professor Moncada's approach is stark. He has harnessed Government and industry in backing an institute dedicated to basic science. That has already won him pledges of support totalling pounds 26m from Government and the Wellcome Trust for the pounds 41.5m capital cost of converting the eponymous Cruciform building of the old University College Hospital in London. On top of that, the drugs industry and academic sources have promised pounds 2.5m of the expected pounds 12m to pounds 14m running costs when the institute opens in the autumn of 1998 with a staff of some 300.

Glaxo Wellcome, the drugs giant which last year subsumed Professor Moncada's former employer, is committing itself to pounds 10m over seven years to pursue research into the effect on septic shock of nitric oxide, the area which Professor Moncada pioneered as head of Wellcome's research efforts in the 1980s. Glaxo Wellcome will keep the intellectual property rights, with the Moncada institute receiving royalties from any new drugs which result from the work.

Outsiders suggest there is the prospect for a whole series of similar deals. Rolf Stahel, another member of the Wellcome diaspora, who is now chief executive of biotech group Shire Pharmaceuticals, says his group and Professor Moncada's are "beautifully complementary".

Shire will be looking hard at fundamental work carried out at the institute in areas such as the central nervous system for potential development prospects. But there will be no millionaire boffins a la British Biotech from new blockbuster cures based on work coming from UCL. The majority of the royalties will be ploughed back into what Professor Moncada emphasises will be basic science. "We are going to do fundamental research as the main point of our activity. I think what we are doing is exploiting the interface between academia and industry," he says.

In the first instance, this will be to apply discoveries in a more efficient way and secondly to fund further fundamental research. "One of the problems [of this country] has been the slow transfer of scientific knowledge into practical applications. That is one of the gaps we want to bridge," he says.

Professor Moncada sees a growing need for a basic research body of this sort, given the trend towards consolidation in the drugs industry. "I think the pressures from the market are forcing the industry to concentrate on development rather than research. My feeling is the drugs industry will rely more and more on academic research and smaller, start-up companies. They will be more efficient and more productive."

But he differentiates Cruciform from biotechnology companies such as British Biotech and Shire. The emphasis of the science used by such companies is on large-scale molecular biology, he says, using proteins and peptides. By contrast, his institute will use smaller molecules and concentrate on how they affect chemical processes, rather than creating drugs or cures for diseases.

It is a noble enterprise, at least as worthy as his attempts to aid his fellow countrymen in Central America, and one that would present a challenge to a young person, let alone a man of 51. But Professor Moncada is used to radical departures, having had literal experience of them in his flights from various dictatorships.

On past form, he will scale this new peak with ease, potentially giving London a new centre of excellence in medicine, not just in research, but in teaching too. The institute should be up and running in time for the planned merger of London's Royal Free, Middlesex and University College medical schools. After that, who knows.

"I have never made long-term plans, although I have done things for a long time," he says. "I have been a scientist for a quarter of a century. I would like to believe that I still will have the flexibility to look for the excitement and go for it, rather than settling."

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Office Manager / Financial Services

£30000 - £37000 per annum: Recruitment Genius: Established in 1999, a highly r...

Jemma Gent: Year End Accountant

£250-£300 Day Rate: Jemma Gent: Are you a qualified accountant with strong exp...

Jemma Gent: Management Accountant

£230 - £260 Day Rate: Jemma Gent: Do you want to stamp your footprint in histo...

Beverley James: Accounts Payable

£22,000 - £23,000: Beverley James: Are you looking for the opportunity to work...

Day In a Page

HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?
How we must adjust our lifestyles to nature: Welcome to the 'Anthropocene', the human epoch

Time to play God

Welcome to the 'Anthropocene', the human epoch where we may need to redefine nature itself
MacGyver returns, but with a difference: Handyman hero of classic 1980s TV series to be recast as a woman

MacGyver returns, but with a difference

Handyman hero of classic 1980s TV series to be recast as a woman
Tunnel renaissance: Why cities are hiding roads down in the ground

Tunnel renaissance

Why cities are hiding roads underground
'Backstreet Boys - Show 'Em What You're Made Of': An affectionate look at five middle-aged men

Boys to men

The Backstreet Boys might be middle-aged, married and have dodgy knees, but a heartfelt documentary reveals they’re not going gently into pop’s good night
Crufts 2015: Should foreign dogs be allowed to compete?

Crufts 2015

Should foreign dogs be allowed to compete?
10 best projectors

How to make your home cinema more cinematic: 10 best projectors

Want to recreate the big-screen experience in your sitting room? IndyBest sizes up gadgets to form your film-watching
Manchester City 1 Barcelona 2 player ratings: Luis Suarez? Lionel Messi? Joe Hart? Who was the star man?

Manchester City vs Barcelona player ratings

Luis Suarez? Lionel Messi? Joe Hart? Who was the star man at the Etihad?
Arsenal vs Monaco: Monaco - the making of Gunners' manager Arsene Wenger

Monaco: the making of Wenger

Jack Pitt-Brooke speaks to former players and learns the Frenchman’s man-management has always been one of his best skills
Cricket World Cup 2015: Chris Gayle - the West Indies' enigma lives up to his reputation

Chris Gayle: The West Indies' enigma

Some said the game's eternal rebel was washed up. As ever, he proved he writes the scripts by producing a blistering World Cup innings
In Ukraine a dark world of hybrid warfare and murky loyalties prevails

In Ukraine a dark world of hybrid warfare

This war in the shadows has been going on since the fall of Mr Yanukovych
'Birdman' and 'Bullets Over Broadway': Homage or plagiarism?

Homage or plagiarism?

'Birdman' shares much DNA with Woody Allen's 'Bullets Over Broadway'
Broadchurch ends as damp squib not even David Tennant can revive

A damp squib not even David Tennant can revive

Broadchurch, Series 2 finale, review
A Koi carp breeding pond, wall-mounted iPads and a bathroom with a 'wellness' shower: inside the mansion of Germany's 'Bishop of Bling'

Inside the mansion of Germany's 'Bishop of Bling'

A Koi carp breeding pond, wall-mounted iPads and a bathroom with a 'wellness' shower